Novavax Says Prepared To Deliver Protein-Based Monovalent XBB COVID Vaccine Consistent With FDA VRBPAC Recommendation For The Fall
Portfolio Pulse from Benzinga Newsdesk
Novavax has developed a protein-based monovalent XBB.1.5 COVID vaccine candidate and plans to deliver it during the fall vaccination campaign. If authorized, it would be the only non-mRNA XBB.1.5 vaccine available in the U.S.
June 15, 2023 | 9:36 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Novavax's protein-based XBB.1.5 COVID vaccine candidate could potentially be the only non-mRNA option in the U.S., targeting fall delivery.
Novavax's protein-based XBB.1.5 COVID vaccine candidate, if authorized, would be the only non-mRNA option available in the U.S. This could lead to increased demand for the vaccine, potentially boosting Novavax's stock price in the short term. The fall delivery timeline also adds a sense of urgency and potential for near-term gains.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100